Search

everythinglearnresearchcommunity

for

Search:↓

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Brodalumab is more effective than ustekinumab for treating psoriasis.

Dupilumab effectively treats severe skin issues in a rare genetic disorder.

DEC cells show promise as a safe and effective treatment for Duchenne muscular dystrophy.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

The rash resolved after stopping ponatinib.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Adalimumab can cause hair loss and scalp issues in some psoriasis patients.